Open Access 24-04-2025 | Endometriosis | Research

Distinct endometriosis involvement confers divergent oncologic outcomes in ovarian clear cell carcinoma

Authors: Jie Deng, Jiayuan Li, Lian Xu, Tianjin Yi

Published in: Archives of Gynecology and Obstetrics

Abstract

Objective

To evaluate the clinicopathologic characteristics and survival outcomes of ovarian clear cell carcinoma (OCCC) patients with different endometriosis statuses.

Methods

This retrospective study included OCCC patients diagnosed between 2012 and 2021, classified into three groups based on the Sampson and Scott criteria: Without (no endometriosis), Arising (OCCC arising from endometriosis), and Coexisting (OCCC coexisting with endometriosis). Clinical and pathological characteristics were compared across groups, and survival outcomes were analyzed using Kaplan–Meier methods. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were identified through univariate and multivariate analyses.

Results

Among 242 patients, 53.7% were in the Without group, 29.3% in the Arising group, and 16.9% in the Coexisting group. The Arising group had the highest prevalence of early FIGO stage disease (91.6%) compared to the Coexisting (75.6%, p = 0.041) and Without (67.7%, p = 0.000) groups. Lymph-node metastasis was significantly lower in the Arising group (2.8%) than in the Coexisting (19.5%, p = 0.010) and Without (10%, p = 0.011) groups. Notably, the Arising group demonstrated unique atypical endometriosis features. In univariate analysis, the presence of endometriosis (either arising from or coexisting with endometriosis) was associated with improved PFS (p = 0.004 and p = 0.009, respectively); however, multivariate analysis confirms only coexisting with endometriosis as an independent factor (HR: 0.11, 95% CI: 0.01–0.84). For OS, the Arising group demonstrated the most significant benefit, with a 5-year OS of 92.4% compared to the Coexisting group (83.9%, p = 0.293) and the Without group (62.6%, p = 0.023). Multivariate analysis identified only FIGO stage (HR: 5.89, 95% CI: 2.06–16.82) as an independent prognostic factor for OS, while endometriosis did not reach statistical significance (HR: 0.62, 95% CI: 0.26–1.53).

Conclusions

Classifying OCCC with endometriosis statuses reveals distinct prognostic patterns. Coexisting with endometriosis positively impacts PFS, while the Arising subgroup shows the most significant OS benefit but may be confounded with other factors.

Available only for authorised users

Burney RO, Giudice LC (2012) Pathogenesis and pathophysiology of endometriosis. Fertil Steril 98(511–519):20120720. https://doi.org/10.1016/j.fertnstert.2012.06.029CrossRef

Kvaskoff M, Mu F, Terry KL et al (2015) Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update 21(500–516):20150311. https://doi.org/10.1093/humupd/dmv013CrossRef

Wischmann T, Ditzen B (2024) Endometriosis: patient-doctor communication and psychological counselling. Arch Gynecol Obstet 309(599–610):20231205. https://doi.org/10.1007/s00404-023-07292-2CrossRef

Pearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(385–394):20120222. https://doi.org/10.1016/s1470-2045(11)70404-1CrossRef

Pectasides D, Pectasides E, Psyrri A et al (2006) Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11:1089–1094. https://doi.org/10.1634/theoncologist.11-10-1089CrossRefPubMed

Machida H, Matsuo K, Yamagami W et al (2019) Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol 153(589–596):20190321. https://doi.org/10.1016/j.ygyno.2019.03.243CrossRef

Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589CrossRefPubMed

Suzuki K, Takakura S, Saito M et al (2014) Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 24:1181–1189. https://doi.org/10.1097/igc.0000000000000178CrossRefPubMed

Ogawa S, Kaku T, Amada S et al (2000) Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 77:298–304. https://doi.org/10.1006/gyno.2000.5765CrossRefPubMed

10.

Park JY, Kim DY, Suh DS et al (2018) Significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma. Int J Gynecol Cancer 28:11–18. https://doi.org/10.1097/igc.0000000000001136CrossRefPubMed

11.

Bai H, Cao D, Yuan F et al (2016) Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: experiences at three academic institutions. Gynecol Oncol 143(526–531):20161013. https://doi.org/10.1016/j.ygyno.2016.10.009CrossRef

12.

Orezzoli JP, Russell AH, Oliva E et al (2008) Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 110(336–344):20080718. https://doi.org/10.1016/j.ygyno.2008.05.025CrossRef

13.

Boyraz G, Selcuk I, Yazıcıoğlu A et al (2013) Ovarian carcinoma associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 170(211–213):20130709. https://doi.org/10.1016/j.ejogrb.2013.06.001CrossRef

14.

Wang S, Qiu L, Lang JH et al (2013) Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis. Am J Obstet Gynecol 208(413):411–415. https://doi.org/10.1016/j.ajog.2012.12.004CrossRef

15.

Mangili G, Bergamini A, Taccagni G et al (2012) Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol 126(403–407):20120515. https://doi.org/10.1016/j.ygyno.2012.05.007CrossRef

16.

Noli S, Cipriani S, Scarfone G et al (2013) Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 23:244–248. https://doi.org/10.1097/IGC.0b013e31827aa0bbCrossRefPubMed

17.

Cuff J, Longacre TA (2012) Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type. Am J Surg Pathol 36:688–695. https://doi.org/10.1097/PAS.0b013e31824b6eedCrossRefPubMed

18.

Bounous VE, Ferrero A, Fuso L et al (2016) Endometriosis-associated ovarian cancer: a distinct clinical entity? Anticancer Res 36:3445–3449PubMed

19.

Kumar S, Munkarah A, Arabi H et al (2011) Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol 204(63):e61-67. https://doi.org/10.1016/j.ajog.2010.08.017CrossRef

20.

Tsuchiya A, Sakamoto M, Yasuda J et al (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503–2512. https://doi.org/10.1016/s0002-9440(10)63605-xCrossRefPubMedPubMedCentral

21.

DeLair D, Oliva E, Köbel M et al (2011) Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 35:36–44. https://doi.org/10.1097/PAS.0b013e3181ff400eCrossRefPubMed

22.

Bulun SE, Monsavais D, Pavone ME et al (2012) Role of estrogen receptor-β in endometriosis. Semin Reprod Med 30(39–45):20120123. https://doi.org/10.1055/s-0031-1299596CrossRef

23.

Sampson JA (1925) Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 10:1–72. https://doi.org/10.1001/archsurg.1925.01120100007001CrossRef

24.

Scott RB (1953) Malignant changes in endometriosis. Obstet Gynecol 2:283–289PubMed

25.

Ju UC, Kang WD, Kim SM (2019) The effect of concurrent endometriosis on the prognosis of women with ovarian clear cell or endometrioid carcinoma. Int J Gynaecol Obstet 146(177–183):20190529. https://doi.org/10.1002/ijgo.12861CrossRef

26.

Qiu L, Wang S, Lang JH et al (2013) The occurrence of endometriosis with ovarian carcinomas is not purely coincidental. Eur J Obstet Gynecol Reprod Biol 170(225–228):20130715. https://doi.org/10.1016/j.ejogrb.2013.06.015CrossRef

27.

Chiaffarino F, Cipriani S, Ricci E et al (2024) Histologic subtypes in endometriosis-associated ovarian cancer and ovarian cancer arising in endometriosis: a systematic review and meta-analysis. Reprod Sci 31(1642–1650):20240304. https://doi.org/10.1007/s43032-024-01489-9CrossRef

28.

Wepy C, Nucci MR, Parra-Herran C (2024) Atypical endometriosis: comprehensive characterization of clinicopathologic, immunohistochemical, and molecular features. Int J Gynecol Pathol 43(70–77):20230313. https://doi.org/10.1097/pgp.0000000000000952CrossRef

29.

Leone Roberti Maggiore U, Bogani G, Paolini B et al (2024) Endometriosis-associated ovarian cancer: a different clinical entity. Int J Gynecol Cancer 34:863–870. https://doi.org/10.1136/ijgc-2023-005139CrossRefPubMed

30.

Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/jco.2002.20.5.1248CrossRefPubMed

31.

Fukunaga M, Nomura K, Ishikawa E et al (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30:249–255. https://doi.org/10.1046/j.1365-2559.1997.d01-592.xCrossRefPubMed

32.

So KA, Hong SR, Kim NR et al (2021) Association between atypical endometriosis and ovarian malignancies in the real world. J Ovarian Res 14(110):20210828. https://doi.org/10.1186/s13048-021-00865-2CrossRef

33.

Guo DH (2008) Pang SJ and Shen Y [Atypical endometriosis: a clinicopathologic study of 163 cases]. Zhonghua Fu Chan Ke Za Zhi 43:831–834PubMed

34.

Varma R, Rollason T, Gupta JK et al (2004) Endometriosis and the neoplastic process. Reproduction 127:293–304. https://doi.org/10.1530/rep.1.00020CrossRefPubMed

35.

Board Whocwhocte 2020 Female Genital Tumours. International Agency for Research on Cancer

36.

Lenz J, Chvatal R, Fiala L et al (2021) Comparative immunohistochemical study of deep infiltrating endometriosis, lymph-node endometriosis and atypical ovarian endometriosis including description of a perineural invasion. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 165(69–79):20200309. https://doi.org/10.5507/bp.2020.006CrossRef

37.

Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(1532–1543):20100908. https://doi.org/10.1056/NEJMoa1008433CrossRef

38.

Zhang M, Xu T, Tong D et al (2023) Research advances in endometriosis-related signaling pathways: a review. Biomed Pharmacother 164(114909):20230519. https://doi.org/10.1016/j.biopha.2023.114909CrossRef

39.

Mandai M, Yamaguchi K, Matsumura N et al (2009) Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 14(383–391):20091025. https://doi.org/10.1007/s10147-009-0935-yCrossRef

40.

AlAshqar A, Reschke L, Kirschen GW et al (2021) Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†. Biol Reprod 105:7–31. https://doi.org/10.1093/biolre/ioab054CrossRefPubMedPubMedCentral

41.

Ye S, Zhou S, Zhong S et al (2022) The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma. BMC Cancer 22(449):20220423. https://doi.org/10.1186/s12885-022-09588-zCrossRef

42.

Gadducci A, Multinu F, Cosio S et al (2021) Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol 162(741–750):20210708. https://doi.org/10.1016/j.ygyno.2021.06.033CrossRef

43.

Yamamoto S, Tsuda H, Takano M et al (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25(615–624):20111209. https://doi.org/10.1038/modpathol.2011.189CrossRef

44.

Worley MJ Jr, Liu S, Hua Y et al (2015) Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer 51(1831–1842):20150606. https://doi.org/10.1016/j.ejca.2015.05.011CrossRef

Title: Distinct endometriosis involvement confers divergent oncologic outcomes in ovarian clear cell carcinoma
Authors: Jie Deng
Jiayuan Li
Lian Xu
Tianjin Yi
Publication date: 24-04-2025
Publisher: Springer Berlin Heidelberg
Keyword: Endometriosis
Published in: Archives of Gynecology and Obstetrics
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-025-08025-3

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Distinct endometriosis involvement confers divergent oncologic outcomes in ovarian clear cell carcinoma

Abstract

Objective

Methods

Results

Conclusions

Women’s health knowledge hub

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Women’s health knowledge hub

Keynote series | Spotlight on menopause